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Abstract
We report that natural killer T (NKT) cells play only a minor physiological role in protection from Leishmania donovani
infection in C57BL/6 mice. Furthermore, attempts at therapeutic activation of invariant NKT (iNKT) cells with a-
galactosylceramide (a-GalCer) during L. donovani infection exacerbated, rather than ameliorated, experimental visceral
leishmaniasis. The inability of a-GalCer to promote anti-parasitic immunity did not result from inefficient antigen
presentation caused by infection because a-GalCer–loaded bone marrow–derived dendritic cells were also unable to
improve disease resolution. The immune-dampening affect of a-GalCer correlated with a bias towards increased IL-4
production by iNKT cells following a-GalCer stimulation in infected mice compared to naı ¨ve controls. However, studies in IL-
4–deficient mice, and IL-4 neutralisation in cytokine-sufficient mice revealed that a-GalCer–induced IL-4 production during
infection had only a minor role in impaired parasite control. Analysis of liver cell composition following a-GalCer stimulation
during an established L. donovani infection revealed important differences, predominantly a decrease in IFNc
+ CD8
+ T cells,
compared with control-treated mice. Our data clearly illustrate the double-edged sword of NKT cell–based therapy, showing
that in some circumstances, such as when sub-clinical or chronic infections exist, iNKT cell activation can have adverse
outcomes.
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Introduction
Natural killer T (NKT) cells are a unique subset of CD1d-
restricted T cells that provide a link between innate and adaptive
immune responses. In mice, invariant NKT (iNKT) cells express a
semi-invariant TCR, consisting of a Va14Ja18 TCR a-chain and
a TCR b-chain biased towards Vb8.2, Vb2, and Vb7 expression
(reviewed in [1]). Type II NKT cells are another cell subset in
mice with more diverse TCR expression [1–3]. Upon stimulation,
iNKT cells rapidly produce large quantities of pro- and anti-
inflammatory cytokines, resulting in activation of other immune
cells such as NK cells and conventional T cells [4–7] (also
reviewed in [8]). NKT cells recognise and respond to glycolipid
antigens presented on CD1d molecules. The most well-defined
antigen for iNKT cells is a-galactosylceramide (a-GalCer), a
marine sponge-derived glycolipid that specifically targets iNKT
cells and no other lymphocyte populations directly [9]. The
activation of iNKT cells by a-GalCer can enhance resistance in
several infectious disease models, including viral, bacterial and
parasitic infections (reviewed in [10–12]). Among parasitic
infections studied, a-GalCer has been shown to enhance resistance
to malaria [13], trypanosomiasis [14] and toxoplasmosis [15].
The ability of iNKT cells to produce IFNc following stimulation
with a-GalCer is important for this therapeutic effect and host
protection during infection, although the robust induction of TNF,
IL-4 and IL-13 by iNKT cells also occurs (reviewed in [8,16,17].
However, the connection between therapeutically induced NKT
cell responses and physiological NKT cell responses is not always
clear. Nevertheless, there are parallels between physiological and
therapeutic NKT cell responses in some disease models. For
example, in experimental tumour models, the growth of
methylcholanthrene (MCA)-induced sarcoma cell lines is restricted
by physiological IFNc produced by endogenous NKT cells [18],
while many other experimental cell lines, including the B16-F10
melanoma are only controlled by NKT cells following therapeutic
activation with a-GalCer, again in an IFNc-dependent manner
[7]. It is also possible that following pathogen challenge, NKT cells
will be exposed to foreign glycolipids, or self glycolipids, that, in
the inflammatory environment, can trigger NKT cell responses
that are similar to those induced by a-GalCer [19–22] (reviewed in
[23]).
Visceral leishmaniasis (VL) is a potentially fatal human disease
caused by infection with Leishmania donovani or L. infantum (chagasi)
[24,25]. Infection of genetically susceptible mice with L. donovani
results in an acute but ultimately resolving infection in the liver
associated with the development of granulomas around infected
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spleen, associated with severe immunopathology [27,28]. Parasite
numbers increase more slowly in the spleen, and total splenic
parasite burdens usually only reach 5–10% of maximum levels in
the liver, often with greater variation between individual mice than
in the livers of the same animals [28,29]. NKT cells have been
shown to regulate CXCL10 expression in the livers of C57BL/6
mice in the early stages of L. donovani infection, an event thought to
be important for hepatic granuloma development [30]. A subset of
mouse NKT cells has also been reported to be activated by L.
donovani lipophosphoglycan presented by host CD1d [31]. Studies
in CD1d-deficient BALB/c mice have also suggested that NKT
cells are important for the efficient control of L. donovani growth
[31]. In addition, infection of immature human DC with L.
infantum results in increased CD1d cell surface expression, and
subsequent increased recognition and killing by IFNc-producing
iNKT cells [32]. CD4
+ NKT cells have also been implicated in
protection against the early stages of cutaneous leishmaniasis
caused by L. major infection in genetically resistant mouse strains
[33]. However, a more recent study has shown that clinical
recovery from L. major infection can occur in NKT cell-deficient
mice in the same time period as wild type mice, despite this early
NKT cell role in protection [34].
Here we investigated the role of NKT cells during experimental
VL in C57BL/6 mice, and tested whether stimulation of iNKT
cells with a-GalCer could enhance anti-parasitic activity. Our data
indicate that NKT cells are neither required for the development
of immunity in the liver, nor for the control of parasite burden in
the spleen following L. donovani infection. Furthermore, iNKT cell
activation by a-GalCer hinders disease resolution in the liver.
These results have important implications for the modulation of
iNKT cell function during established disease.
Results
The Role of NKT Cells in the Control of L. donovani
Infection in C57BL/6 Mice
To determine the relative roles of iNKT cells and type II NKT
cells during experimental VL, we infected C57BL/6 mice deficient
in iNKT cells only (B6.Ja18
2/2) and all CD1d-restricted NKT
cells (B6.CD1d
2/2) with L. donovani and compared their course of
infection to C57BL/6 controls. Only minor differences in parasite
burdens were found between NKT cell-deficient mice and
C57BL/6 controls. B6.Ja18
2/2 mice had significantly higher
hepatic parasite burdens than C57BL/6 mice at day 56 post-
infection (p.i.) (p,0.05; Figure 1A), suggesting that iNKT cells may
be required for optimal control of parasite growth at later stages of
infection. However, C57BL/6 and B6.Ja18
2/2 mice had resolved
hepatic infection to a similar extent by day 90 and 180 p.i. (liver
parasite burdens were 93642 Leishman-Donovan units (LDU)
versus 119636 LDU in C57BL/6 versus B6.Ja18
2/2 mice at day
90 p.i., and 0.460.5 LDU versus 6.263.0 LDU in C57BL/6
versus B6.Ja18
2/2 mice at day 180 p.i.). A small but significant
difference (p,0.05) in hepatic parasite burdens was also observed
between B6.CD1d
2/2 and C57BL/6 mice at day 7 p.i. (Figure 1A)
suggesting a minor role for type II NKT cells in the early control
of L. donovani growth. Alternatively, the CD1d molecule itself may
signal to antigen presenting cells independently of NKT cells [35],
thereby contributing to anti-parasitic immunity. B6.CD1d
2/2
mice had resolved hepatic L. donovani infection to the same extent
as C57BL/6 control mice by day 56 p.i. (Figure 1A), and were not
examined after this time point. There was no decrease in the total
Author Summary
Natural killer T (NKT) cells are a unique subset of T cells
that can produce large quantities of inflammatory
cytokines very rapidly upon stimulation. They are known
to be strongly stimulated by a molecule called a-
galactosylceramide (a-GalCer) that is derived from a
marine sponge, and in this way a-GalCer is hoped to
provide effective immunotherapy for a wide range of
diseases. We attempted to stimulate NKT cells with a-
GalCer in mice infected with Leishmania donovani,a
protozoan parasite that causes a chronic disease known
as visceral leishmaniasis in humans. L. donovani character-
istically causes an acute resolving infection in the liver
where NKT cells are abundant. Therefore, we hypothesised
that by stimulating these cells with a-GalCer we would
improve the rate of hepatic disease resolution. However,
while a-GalCer administered prior to infection had no
effect on hepatic parasite burden, a-GalCer administered
during an established infection exacerbated hepatic
disease, associated with a decrease in IFNc-producing
CD8
+ T cells. These results are important as they
demonstrate that therapies aimed at modulating NKT cell
function are not always beneficial, and adverse conse-
quences may occur in certain circumstances, such as in the
presence of persistent and/or sub-clinical infections.
Figure 1. NKT Cells Are Not Required for Control of L. donovani Infection. Female C57BL/6 (closed squares), B6.Ja18
2/2 (open circles) and
B6.CD1d
2/2 (open triangles) mice were infected with L. donovani, and parasite burdens were monitored from day 7 to day 56 p.i. in the liver (A) and
spleen (B). Data represent the mean6SEM of parasite burdens (LDU) from four mice per group for each time point. One representative experiment of
two performed with similar outcome is shown. Significant differences of p,0.05 between C57BL/6 and B6.Ja18
2/2 mice (#) and C57BL/6 and
B6.CD1d
2/2 mice (*) are indicated.
doi:10.1371/journal.ppat.1000028.g001
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by ELISPOT at any time point in any group of mice (Figure S1).
In addition, parasite burdens in the spleen were similar in all three
groups of mice throughout the first 56 d of infection (Figure 1B)
and until day 180 p.i. in C57BL/6 and B6.Ja18
2/2 mice (splenic
parasite burdens were 24617 LDU versus 1865 LDU in C57BL/
6 versus B6.Ja18
2/2 mice at day 90 p.i., and 563 LDU versus
1063 LDU in C57BL/6 versus B6.Ja18
2/2 mice at day 180 p.i.).
Therefore, control of parasite growth in the liver was achieved in
the absence of both iNKT and type II NKT cells, with only minor
roles for these cells at different times following infection.
Activation of iNKT Cells with a-GalCer at the Time of L.
donovani Infection Does Not Improve Disease Resolution
The links between physiological NKT cell responses and iNKT
responses induced by ligands such as a-GalCer are not always
apparent [8], and even though we were unable to detect a clear
physiological role for NKT cells in protection against L. donovani,i t
was important to determine whether therapeutic iNKT cell
activation with a-GalCer could improve disease resolution.
Therefore, we next tested whether iNKT cells could be activated
by a-GalCer at the time of infection to improve control of L.
donovani growth. We focused these studies on the liver because
NKT cells comprise a major cell population in this tissue site and
parasite burdens are significantly higher and more consistent in
the liver than in the spleen. The activity of a-GalCer was
confirmed prior to all experiments by measuring IFNc production
by hepatic iNKT cells 2 h following a-GalCer administration
(data not shown). A single injection of a-GalCer was administered
so that the iNKT cell response was not tolerised or biased towards
a Th2 response, as has previously been reported [12,36–38]. First,
a-GalCer was administered the day prior to infection, and no
differences in hepatic parasite burdens were observed in treated
mice, compared with controls on day 14 p.i. (Figure 2A). The same
result was observed when a-GalCer was administered to mice 2 h
prior to infection (Figure 2B). Stimulation with a-GalCer–loaded
bone marrow–derived dendritic cells (BMDC) results in more
prolonged cytokine responses than with soluble a-GalCer in mice
due to selective targeting of the glycolipid to DC and improved
presentation of the antigen to iNKT cells [37]. L. donovani has also
been shown to interfere with antigen processing pathways [39].
Although there is no direct evidence for CD1d antigen
presentation being compromised during experimental VL, we
sought to eliminate this possibility by delivering a-GalCer–loaded
BMDC to mice 2 h prior to infection. However, despite the
stimulation of efficient iNKT cell activation by a-GalCer–loaded
BMDC, demonstrated by increased serum cytokine levels (data not
shown), and as previously reported [37] this mode of a-GalCer
delivery also had no impact on hepatic parasite burdens relative to
control mice that had received vehicle-loaded BMDC (Figure 2B).
a-GalCer Treatment at the Time of iNKT Cell Activation in
Response to L. donovani Infection Enhances Parasite
Growth
We next determined whether and when iNKT cells were first
activated in response to L. donovani infection, so that we could test
whether a-GalCer stimulation at this time was effective at
activating these cells for anti-leishmanial effects. Although the
percentage of iNKT cells in the liver was reduced at day 14 p.i.
(Figure 3A), due to the hepatic recruitment of other leukocytes
during granuloma formation (reviewed in [26]), total iNKT cell
numbers doubled by day 7 p.i., and this increase was sustained at
day 14 p.i. (Figure 3B) due to an approximate 10-fold increase in
total liver mononuclear cell (MNC) number. There was also
evidence of TCR down-regulation by iNKT cells at day 7 p.i.
(data not shown) and day 14 p.i. (Figure 3A), but not earlier,
suggesting TCR-dependent NKT cell activation, as seen following
a-GalCer stimulation [40–42]. Furthermore, NK1.1 expression on
iNKT cells was also reduced at these times, consistent with
activation of these cells (Figure 3C). The expression of CD69 on
iNKT cells also increased above normal intermediate levels
following L. donovani infection from day 7 p.i. onwards (Figure 3C
and 3D). Together, these data suggested that day 7 p.i. was an
appropriate time to stimulate iNKT cells with a-GalCer to
coincide with the time when hepatic iNKT cells were naturally
activated following L. donovani infection. However, when C57BL/6
mice were given a-GalCer at this time, there was a significant
increase in hepatic parasite burdens on day 14 p.i. (p,0.05),
relative to controls (Figure 3E). Thus, a-GalCer–stimulation of
iNKT cells at the time when activation occurred naturally during
infection suppressed, rather than improved, control of parasite
growth in the liver.
Treatment with a-GalCer during an Established L.
donovani Infection Impairs Disease Resolution in the
Liver
To test whether the activation of iNKT cells during
an established L. donovani infection had any therapeutic potential,
Figure 2. Stimulation of iNKT Cells with a-GalCer at the Time of Infection Does Not Enhance the Early Control of L. donovani Growth
in the Liver. C57BL/6 mice were injected i.p. with either vehicle control (open bars) or 2 mg a-GalCer (closed bars) the day prior to L. donovani
infection. Parasite burdens were determined at day 14 p.i. and data represent the mean6SEM of parasite burdens (LDU) from four mice per group (A).
C57BL/6 mice were injected i.p. with either vehicle control (open bars) or 2 mg a-GalCer (closed bars), or i.v. with 5610
5 vehicle-pulsed BMDC (open
bars) or a-GalCer-pulsed BMDC (closed bars) 2 h prior to L. donovani infection, as indicated (B). Parasite burdens were determined in the liver at day
14 p.i. and data represent the mean6SEM of parasite burdens (LDU) from four mice per group.
doi:10.1371/journal.ppat.1000028.g002
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time of peak hepatic parasite burden in C57BL/6 mice (Figure 1A).
Mice were sacrificed 1 wk later, and again, there were significant
increases (p,0.05) in hepatic parasite burdens in mice that
received a-GalCer, compared to controls (Figure 4A). When a-
GalCer–loaded BMDC were used instead of soluble a-GalCer,
there were no significant changes in hepatic parasite burdens,
compared with controls that received vehicle-loaded BMDC
(Figure 4A). Serum TNF levels were reduced in a-GalCer-treated
mice on day 21 p.i. compared to controls (p,0.05), but this did not
occur in mice that received a-GalCer-loaded BMDC compared to
controls that received vehicle-loaded BMDC (Figure 4B). A similar
Figure 3. The Number of iNKT Cells and the Expression of CD69 by iNKT Cells Are Increased in the Liver by Day 7 after Infection,
Yet Stimulation with a-GalCer at This Time Enhances Hepatic Parasite Growth. (A–D) C57BL/6 mice were infected with L. donovani, and
killed at various time points p.i. for analysis of hepatic iNKT cells by flow cytometry. (A) iNKT cells were enumerated by labelling with CD1d/a-GalCer
tetramers and anti-abTCR, depicted for a naı ¨ve liver, and at day 14 p.i., as indicated. The numbers in the top right hand corner represent the
mean6SEM of gated cells. (B) The absolute number of hepatic TCRb
+ tetramer
+ iNKT cells at each time point. (C) The surface expression of NK1.1 and
CD69 (early activation marker) is shown on gated hepatic NKT cells from a naı ¨ve animal (grey line) and at day 14 p.i. (solid black line). (D) Total
number of hepatic NKT cells expressing enhanced levels of CD69, relative to naı ¨ve mice. All data are from three mice per time point, and data in (B)
and (D) represent the mean frequency6SEM for each time point. (E) C57BL/6 mice were infected with L. donovani and treated with either vehicle
control (open bars) or 2 mg a-GalCer (closed bars) on day 7 p.i. Parasite burdens were determined in the liver at day 14 p.i. and data represent the
mean6SEM of parasite burdens (LDU) from four mice per group. Statistical differences of p,0.01 (**) for vehicle versus a-GalCer treatment are
indicated.
doi:10.1371/journal.ppat.1000028.g003
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that received either soluble a-GalCer or a-GalCer–loaded BMDC
compared to controls, but these differences were not statistically
significant (Figure 4C). It should also be noted that vehicle-pulsed
BMDC caused small reductions in serum TNF and IFNc levels,
relative to mice receiving vehicle alone (Figure 4B and 4C),
suggesting that a DC-derived mediator might contribute to anti-
protective effects seen following a-GalCer treatment. Thus,
stimulation of iNKT cells with a-GalCer during an established
infection, either in soluble form or loaded onto DC, did not
improve disease control, and furthermore, soluble a-GalCer
enhanced parasite growth in mice with an established infection.
To determine whether a-GalCer–treated mice recovered at
later time points, a-GalCer was administered on day 14 p.i., and
mice were sacrificed on both day 21 p.i. and day 70 p.i. (Figure
S2). At day 70 p.i., hepatic parasite burdens had diminished
significantly in mice receiving either vehicle or a-GalCer, and
there was no significant difference between the groups. Therefore,
the anti-protective effects of a single dose of a-GalCer during an
established infection were transient, and anti-parasitic mechanisms
were ultimately re-established in treated mice.
IL-10 Does Not Impede the Function of iNKT Cells During
L. donovani Infection
L. donovani infection results in the generation of immune
regulatory mechanisms that prevent efficient disease resolution.
In particular, IL-10 suppresses pro-inflammatory responses and
parasite clearance during experimental VL [27,43–45]. Previous
work has reported an expansion of IL-10–producing CD4
+ T cells
in mice following L. donovani infection [46], and more recently,
high levels of IL-10 mRNA accumulation were found in T cells
isolated from splenic aspirates taken from Indian VL patients [47].
Furthermore, activated NKT cells are capable of IL-10 production
[48]. Therefore, mice were treated with either anti–IL-10 receptor
(IL-10R) mAb or control rat IgG on day 12 p.i., 2 d prior to the
administration of a-GalCer. Liver parasite burdens were measured
1 wk following a-GalCer treatment. Again, the administration of
a-GalCer to control mice on day 14 p.i. resulted in increased
hepatic (p,0.05) parasite burdens compared to vehicle-treated
controls (Figure 5A). IL-10R blockade was extremely potent in
reducing parasite burdens (Figure 5A), as previously reported [43].
Stimulation of iNKT cells with a-GalCer in the absence of IL-10
signalling did not have an additive effect on the control of parasite
growth, compared to vehicle-treated controls (Figure 5A), but
instead resulted in a small, but significant (p,0.01), increase in
hepatic parasite burdens (Figure 5A). IL-10 blockade led to
significantly elevated levels of serum TNF in both vehicle and a-
GalCer treated mice (p,0.01; Figure 5B), and a significant
increase in serum IFNc in mice that received a-GalCer (p,0.05;
Figure 5C). However, a-GalCer treatment resulted in increased
hepatic parasite burdens despite these increased levels of
inflammatory cytokines. a-GalCer treatment reduced the levels
of serum TNF but not IFNc relative to vehicle treatment in mice
that received IL-10R blockade. Thus, stimulation of iNKT cells
with a-GalCer in the absence of IL-10 signalling during an
established L. donovani infection did not reduce parasite burdens in
the liver, thereby indicating that this mechanism of immune
regulation was not responsible for the failure of a-GalCer to
improve control of parasite growth.
Figure 4. Stimulation of iNKT Cells with a-GalCer during an Established Infection Exacerbates L. donovani Growth in the Liver. C57BL/
6 mice were infected with L. donovani and treated with either vehicle control (open bars) or 2 mg a-GalCer (closed bars) i.p., or injected i.v. with 5610
5
vehicle-pulsed BMDC (open bars) or a-GalCer-pulsed BMDC (closed bars) on day 14 p.i.. Parasite burdens were determined in the liver at day 14 p.i. in
untreated mice (grey bars; base-line parasite burden) and 1 wk later in treated groups, as indicated (A). Data represent the mean6SEM of parasite
burdens (LDU) from four mice per group. Serum TNF (B) and IFNc (C) levels at indicated time points are also shown. Statistical differences of p,0.05
(*) for vehicle versus a-GalCer treatment are indicated.
doi:10.1371/journal.ppat.1000028.g004
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Hepatic Regulatory Cytokine Production in Response to
a-GalCer Stimulation
We next examined whether iNKT cells responded differently to
a-GalCer stimulation during an established L. donovani infection.
Naı ¨ve and infected mice (day 14 p.i.) were administered a-GalCer
and sacrificed 2 h later. The down-regulation of TCR on iNKT
cells following a-GalCer stimulation was noted in naı ¨ve mice
(Figure 6A), as previously described [40], as was down-regulation
of TCR on iNKT cells during experimental VL (Figure 6A). L.
donovani infection did not alter the ratio of CD4
+ to CD4
2 iNKT
cells in the liver, and therefore did not appear to selectively favour
the expansion of a particular subset of iNKT cells (data not
shown). IFNc was readily detected in hepatic iNKT cells (Figure
6B), NK cells and conventional T cells (Figure S3) by day 14 p.i..
Following a-GalCer stimulation, the frequency of hepatic iNKT
cells producing IFNc and TNF was significantly reduced in
infected animals relative to naı ¨ve animals (p,0.05), while the
frequency of hepatic iNKT cells producing IL-4 was significantly
increased (p,0.05; Figure 6B–6D). However, due to the increase
in liver MNC number that had occurred by day 14 p.i.
(3.3610
661.8610
5 versus 3.5610
767.9610
6 in naı ¨ve versus
day 14 p.i., respectively), there was an approximate 3-fold increase
in the absolute number of IL-4–producing hepatic iNKT cells, but
little difference in the absolute numbers of IFNc-producing and
TNF-producing iNKT cells following a-GalCer stimulation in
infected mice relative to a-GalCer–treated naı ¨ve controls. These
data suggest an iNKT cell bias towards Th2 cytokine production
in the liver following a-GalCer stimulation during L. donovani
infection. Importantly, there was also an increase in the number of
hepatic NK cells producing IFNc following a-GalCer stimulation
in infected animals relative to a-GalCer–treated naı ¨ve animals
(p,0.05; 8.2610
465.3610
3 versus 6.7610
561.7610
5 in naı ¨ve
versus day 14 p.i., respectively), indicating that L. donovani infection
does not interfere with this important a-GalCer–mediated effector
pathway.
To determine whether there was a general enhancement in Th2
and/or regulatory cytokine production in response to a-GalCer
Figure 5. IL-10R Blockade Prior to a-GalCer Stimulation Does Not Improve Control of Parasite Growth During an Established
Infection. (A) C57BL/6 mice were infected with L. donovani and treated with anti–IL-10R mAb or control rat IgG on day 12 p.i., as indicated. Two days
later, mice were treated with vehicle control (open bars) or 2 mg a-GalCer (closed bars) i.p., and parasite burdens were determined in the liver 1 wk
later. Parasite burdens were also determined in untreated mice at day 14 p.i. (grey bars; base-line parasite burden), and at day 21 p.i. in mice that
received no antibody treatment, as indicated. Data represent the mean6SEM of parasite burdens (LDU) from four mice per group. (B) Serum TNF and
(C) IFNc levels at indicated time points are also shown. Statistical differences of p,0.05 (*) for vehicle versus a-GalCer treatment are indicated.
doi:10.1371/journal.ppat.1000028.g005
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Hepatic iNKT Cells Producing IFNc and TNF, and an Increased Frequency of Hepatic iNKT Cells Producing IL-4. C57BL/6 mice were
infected with L. donovani and on day 14 p.i., infected mice and uninfected controls were treated with vehicle control or 2 mg a-GalCer i.p. and killed
2 h later for FACS analysis of iNKT cell intracellular cytokine production. Hepatic lymphocytes were labelled with CD1d/a-GalCer tetramers and anti-
abTCR, and iNKT cells were electronically gated as shown (A). The mean6SEM of the percentage of gated cells for each group is shown in the top
right-hand corner. From left to right data represent: naı ¨ve mice that received vehicle control, naı ¨ve mice that received a-GalCer, infected mice that
received vehicle control on day 14 p.i., and infected mice that received a-GalCer on day 14 p.i.. Hepatic iNKT cells were examined for expression of
NK1.1 and intracellular IFNc (B), TNF (C), IL-4 (D), or rat IgG1 (E) (isotype control). Regions were set based on background levels of the isotype control
as shown, and the numbers expressed in the bottom right hand corner are the mean6SEM in this region for each group (4 mice per group).
doi:10.1371/journal.ppat.1000028.g006
NKT Cells and Experimental VL
PLoS Pathogens | www.plospathogens.org 7 2008 | Volume 4 | Issue 2 | e1000028treatment in L. donovani–infected mice, we next measured hepatic
IL-10, TGFb, IL-13 and IL-4 mRNA accumulation at day 21 p.i.
in mice that had received either vehicle or a-GalCer at day 14 p.i.
(Figure 7A–7D). We found no significant differences in hepatic IL-
10 (Figure 7A) or TGFb (Figure 7B) mRNA accumulation
between vehicle- and a-GalCer–treated mice. Similar to the
increased iNKT cell IL-4 production observed 2 h following a-
GalCer administration shown above, we found a significant
(p,0.05) increase in hepatic IL-4 mRNA accumulation (Figure 7C)
1 wk following a-GalCer administration, relative to vehicle-treated
controls. Interestingly, we also found a similar increase (p,0.01) in
hepatic IL-13 mRNA accumulation (Figure 7D) at the same time.
Therefore, a-GalCer treatment of L. donovani–infected mice did
not cause a general increase in Th2 and/or regulatory cytokine
production, but instead, resulted in a selective increase in IL-4 and
IL-13 production.
We next tested whether increased IL-4 production following a-
GalCer stimulation during an established L. donovani infection was
responsible for impaired disease resolution. C57BL/6 and B6.IL-
4
2/2 mice were infected and administered a-GalCer or vehicle
control 14 days later. At this time, B6.IL-4
2/2 mice had similar
hepatic parasite burdens to C57BL/6 mice (Figure 8A). a-GalCer
treatment resulted in increased hepatic parasite burdens (p,0.05)
in both C57BL/6 and B6.IL-4
2/2 mice, compared to vehicle-
treated controls (Figure 8A). To ensure that redundancies in IL-4
deficient mice were not influencing the outcome of these
experiments, we also neutralised IL-4 activity in C57BL/6 mice
using a mAb at a dose previously shown to improve control of L.
donovani growth in a Th2 environment [49] (Figure 8B). Again, we
found that L. donovani-infected mice treated with a-GalCer had
significantly higher (p,0.01) hepatic parasite burdens, compared
with vehicle controls, regardless of whether they received anti–IL-
4 mAb or control rat IgG. Together, these data suggest that
increased IL-4 production in response to a-GalCer treatment in L.
donovani–infected mice, either by iNKT cells or another cell type
following iNKT cell activation, could not alone explain the
impaired clearance of parasites.
Treatment with a-GalCer during an Established L.
donovani Infection Alters Liver Cell Composition and
Cytokine Production
To test whether the activation of iNKT cells during an
established L. donovani infection had any impact on the cellular
composition of the liver that could explain the impaired parasite
clearance, a-GalCer was administered on day 14 p.i., and the
numbers of different hepatic mononuclear cell populations were
assessed 7 d later. We found no significant differences in hepatic B
cell, NKT cell, neutrophil, monocyte/macrophage or DC
numbers in mice that had received a-GalCer, relative to vehicle-
treated control animals (Figure S4). However, we did observe a
Figure 7. Th2 and Regulatory Cytokine mRNA Accumulation in the Liver Following a-GalCer Treatment during an Established L.
donovani Infection. C57BL/6 mice were infected with L. donovani and treated with vehicle control (open bars) or 2 mg a-GalCer (closed bars) i.p. on
day 14.p.i.. IL-10 (A), TGFb (B), IL-4 (C), and IL-13 (D) mRNA accumulation were determined in the liver 1 wk later, as indicated. Cytokine mRNA
accumulation was also determined in naı ¨ve mice (hatched bars) and untreated mice at day 14 p.i. (grey bars). Data represent the mean6SEM of
cytokine mRNA accumulation from four mice per group. Statistical differences of p,0.05 (*) and p,0.01 (**) for vehicle versus a-GalCer treatment are
indicated.
doi:10.1371/journal.ppat.1000028.g007
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+ T cells (Figure 9A)
and a larger, significant (p,0.05) decrease in the number of
hepatic CD8
+ T cells 7 d after a-GalCer-treatment (Figure 9B)
relative to controls. We also found a small, but significant (p,0.05)
increase in hepatic NK cell numbers at the same time (Figure 9C).
We next examined whether the activation status of various cell
populations had been altered by a-GalCer administration at day
14 p.i.. We first focused on both hepatic DC and monocytes/
macrophages and found no alterations in the expression of MHC-
II, CD40, CD80 or CD86 on either population at 1, 2, 3, or 7 d
following a-GalCer treatment, compared with vehicle-treated
controls (data not shown). In addition, TNF production by
monocytes/macrophages was not different between treatment
groups at these times after infection, and no TNF was detected in
DC (data not shown). Therefore, the activation status of the major
hepatic antigen-presenting cell populations did not appear to be
modulated by a-GalCer. To investigate whether lymphocyte
activation had been altered, we examined IFNc production
following a-GalCer or vehicle treatment and found no difference
in the number of hepatic IFNc
+ NK cells (Figure 9C) or IFNc
+
NKT cells (data not shown) by 7 d post-treatment. However, we
did observe a small decrease in the number of IFNc
+ CD4
+ T cells
(Figure 9A) and a larger, significant (p,0.05) decrease in the
number of IFNc
+ CD8
+ T cells 7 d after a-GalCer-treatment
(Figure 9B). Given the importance of IFNc [50] and CD8
+ T cells
[51] for the effective resolution of hepatic L. donovani infection, this
loss of IFNc
+ CD8
+ T cells after a-GalCer treatment is a likely
explanation for the enhanced parasite growth observed in our
studies.
Discussion
We report that CD1d-restricted NKT cells have only a minor
physiological role in experimental VL in C57BL/6 mice. More
importantly, our results indicate that intentional stimulation of
iNKT cells with the glycolipid a-GalCer during L. donovani
infection can exacerbate disease. This suggests that the therapeutic
use of NKT cell activators, such as a-GalCer, may not always
provide beneficial effects, particularly in situations where sub-
clinical or chronic infection may be present.
Previous studies in CD1d-deficient BALB/c mice suggested that
NKT cells were required for efficient control of hepatic L. donovani
infection [31]. The most likely explanation for this discrepancy
with our data is a different requirement for NKT cells in C57BL/6
and BALB/c mice, possibly reflecting different kinetics of parasite
control between these mouse strains [28]. Alternatively, NKT cell
responses may be influenced by host genetic background, as
previously reported in experimental cerebral malaria [52].
Another study in B6.Ja18
2/2 mice suggested that NKT cells
were required for the efficient induction of CXCL10 production
during the early stages of L. donovani infection in the liver [30].
However, given the limited differences observed in hepatic
parasite burdens between B6.Ja18
2/2 mice and control mice at
early time points (Figure 1A), our data suggest that NKT-
independent chemokine signals can compensate for this lack of
early CXCL10 production.
Although only a limited physiological role was found for CD1d-
restricted NKT cells during experimental VL, the activation of
these cells has been shown to improve disease outcome in many
infections, often via the increased production of IFNc [11–15,53].
This can occur even when there appears to be little requirement
for NKT cells during natural infection, and is often due to
downstream activation of NK cells. For example, although iNKT
cells have only a minor role in the clearance of murine
cytomegalovirus, the activation of iNKT cells by a-GalCer during
infection resulted in reduced viral replication in visceral organs
[53]. However, despite iNKT cell IFNc and TNF production, and
Figure 8. IL-4 Production following a-GalCer Stimulation
during an Established L. donovani Infection Has Only a Minor
Role in the Impaired Control of Parasite Growth. (A) C57BL/6
mice and B6.IL-4
2/2 mice were infected with L. donovani and treated
with vehicle control (open bars) or 2 mg a-GalCer (closed bars) i.p. on
day 14 p.i., and parasite burdens were determined in the liver 1 wk
later. Parasite burdens were also determined in untreated mice at day
14 p.i. (grey bars; baseline parasite burden). Data represent the
mean6SEM of parasite burdens (LDU) from four mice per group. (B)
C57BL/6 mice were also infected with L. donovani and treated with
anti–IL-4 mAb or control rat IgG on days 14, 16 and 18 p.i., as indicated.
Following mAb injection on day 14 p.i. mice were treated with vehicle
control (open bars) or 2 mg a-GalCer (closed bars) i.p., and parasite
burdens were determined in the liver 1 wk later. Parasite burdens were
also determined in untreated mice at day 14 p.i. (grey bars; base-line
parasite burden). Data represent the mean6SEM of parasite burdens
(LDU) from four mice per group. Statistical differences of p,0.01 (**) for
vehicle versus a-GalCer treatment are indicated.
doi:10.1371/journal.ppat.1000028.g008
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GalCer administration during infection, the control of L. donovani
was not improved. In fact, a-GalCer treatment during an
established infection suppresses parasite clearance from the liver.
In contrast, the administration of another strong inducer of a Th1
response, recombinant IL-12, does enhance disease resolution in
experimental VL [54], indicating that a-GalCer has a different
qualitative effect despite its ability to induce a strong Th1 response
in L. donovani-infected mice. This may be related to the ability of a-
GalCer to stimulate both Th1 and Th2 cytokine production.
Figure 9. Changes in Liver Cell Composition and IFNc
+ Cell Numbers following a-GalCer Treatment during an Established L.
donovani Infection. C57BL/6 mice were infected with L. donovani and treated with vehicle control (open bars) or 2 mgo fa-GalCer (closed bars) i.p.
on day 14 p.i. The number of hepatic CD4
+ T cells (A), CD8
+ T cells (B), and NK cells (C) were determined 7 d later, as was the number of these cells
producing IFNc, as indicated. Cell composition was also determined in naı ¨ve mice (hatched bars) and untreated mice at day 14 p.i. (grey bars). Data
represent the mean6SEM of cell numbers from four mice per group. Statistical differences of p,0.05 (*) and p,0.01 (**) for vehicle versus a-GalCer
treatment are indicated.
doi:10.1371/journal.ppat.1000028.g009
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parasite growth before and after infection is unclear, but it seems
likely that changes in local tissue environments during infection
may alter the outcome of iNKT cell activation with an impact on
anti-leishmanial immunity. This explanation is supported by the
finding that the timing of a-GalCer administration was also critical
to the effect on murine experimental conjunctivitis [55]. The effect
of other regimes of a-GalCer therapy, other sites of administration
and/or other analogues such as a-C-GalCer [56,57] have not yet
been tested in experimental VL, and it remains possible that these
other strategies might represent a therapeutic regime by which
iNKT cell activation may improve disease resolution in this model.
However, our data clearly show that a-GalCer therapy can
exacerbate disease in L. donovani-infected mice.
A major functional change following a-GalCer-stimulation
during L. donovani infection in the current study was rapidly
increased numbers of IL-4 producing hepatic iNKT cells and a
sustained increase in hepatic IL-4 mRNA accumulation 1 wk
later. However, when L. donovani–infected B6.IL-4
2/2 mice were
treated with a-GalCer, hepatic parasite burdens were still
increased compared to vehicle-treated B6.IL-4
2/2 mice. A similar
failure to reverse the immune-dampening effect of a-GalCer was
also found when mice were treated with anti–IL-4 mAb before and
after a-GalCer treatment. Therefore, the increased a-GalCer
induced IL-4 production by iNKT cells or another hepatic cell
population during L. donovani infection could not alone explain the
enhanced hepatic parasite growth. It is possible that the induction
of other Th2 and/or regulatory cytokines by a-GalCer might
contribute to the increased parasite burden observed. Although no
a-GalCer–related increase in hepatic IL-10 or TGFb mRNA
accumulation was found, we did observe a significant increase in
IL-13 mRNA accumulation. Studies in IL-13–deficient mice
indicate that IL-13 itself does not influence resistance to L. donovani
infection [58]. However, the enhanced production of both IL-4
and IL-13 may work together to exacerbate parasite growth. This
possibility is currently being examined.
Other major changes observed in a-GalCer–treated infected
mice were alterations to liver cell composition. Total hepatic NK
cell number increased in mice that received a-GalCer, yet the
number of IFNc
+ NK cells remained similar to vehicle-treated
mice. NK cells can produce regulatory cytokines and modulate
antigen presenting cell function (reviewed in [59]) and in this way
NK cells may have contributed to the enhanced parasite growth
seen following a-GalCer treatment. Studies to further elucidate the
impact of NK cells on the immune dampening effect of a-GalCer
in L. donovani-infected mice are underway. The other significant
change in liver cell composition that occurred in a-GalCer–treated
mice was a decrease in the number of CD8
+ T cells, and
importantly, a decrease in the number of IFNc
+ CD8
+ T cells.
Previous studies by Murray and colleagues have demonstrated a
critical role for both CD8
+ T cells [51] and IFNc [50] for the
effective resolution of hepatic L. donovani infection. Thus, it is likely
that such a change to CD8
+ T cell effector numbers will have a
major impact on the ability of an animal to control parasite
growth. The reason for this reduction in CD8
+ T cell number is
currently unknown, but could involve enhanced activation-
induced cell death (AICD) and/or failure of expansion in this
cell population. These possibilities are being investigated.
In summary, our data indicate that although NKT cells have a
relatively minor physiological role in experimental VL, intentional
stimulation of iNKT cells with a-GalCer can exacerbate infection.
This finding is significant because it highlights the fact that
therapies aimed at modulating NKT cell function are not always
beneficial to the host, and it is important to take into account the
possibility of adverse consequences, such as may occur in the
presence of pre-existing infections.
Materials and Methods
Mice
Female C57BL/6 and BALB/c mice were purchased from the
Australian Resource Centre (Canning Vale, Western Australia), and
maintained under conventional conditions. B6.RAG1/J
2/2 mice
were bred at the Queensland Institute of Medical Research.
B6.Ja18
2/2 mice [60] were bred at the Peter MacCallum Cancer
Centre and the Queensland Institute of Medical Research.
B6.CD1d
2/2 mice [61] and B6.IL-4
2/2 mice (B6 Il4
tm1Nnt,T h e
Jackson Laboratory, Bar Harbor, ME) [62] were bred at the Peter
MacCallum Cancer Centre. These mouse strains were originally
generated on either the C57BL/6 background or the 129sv
background and backcrossed 10 or more generations to C57BL/6
mice before use. Mice used were sex- and age-matched (6–10 wk),
and all animal procedures were approved by the Queensland
Institute of Medical Research Animal Ethics Committee.
Parasites and infection of mice
L. donovani (LV9) was maintained by passage in BALB/c or
B6.RAG1/J
2/2 mice, and amastigotes were isolated from the
spleens of chronically infected mice. Mice were infected by
injecting 2610
7 amastigotes i.v. via the lateral tail vein, killed at
the times indicated in the text by CO2 asphyxiation and bled via
cardiac puncture. Spleens and perfused livers were removed, and
parasite burdens were determined from Diff-Quick-stained
impression smears (Lab Aids, Narrabeen, Australia) and expressed
in Leishman-Donovan units (LDU) (the number of amastigotes per
1,000 host nuclei multiplied by the organ weight in grams) [63].
Hepatic mononuclear cells (MNC) and splenocytes were isolated
immediately following death as previously described [64,65].
Antibodies
Allophycocyanin (APC)-conjugated anti-TCRb chain, phycoer-
ythrin (PE)-conjugated anti-CD8a, PE-Cy5-conjugated anti-CD4,
PE-conjugated anti-Ly6G, fluorescein isothiocyanate (FITC)-
conjugated anti-Ly6C, APC-conjugated anti-B220, FITC-conju-
gated anti-CD19, APC-conjugated anti-CD11c, FITC-conjugated
anti–I-A/I-E (MHC-II), PE-Cy5-conjugated anti-CD11b, PE-
conjugated anti-CD69, PE-conjugated anti-IFNc, PE-conjugated
anti-TNF, PE-conjugated anti–IL-4, PE-conjugated rat IgG1, PE-
conjugated rat IgG2a, and biotinylated anti-NK1.1 mAbs were
purchased from Biolegend (San Diego, CA) or BD Biosciences
(Franklin Lakes, NJ). PE-Cy5-conjugated a-GalCer–loaded or
vehicle-loaded mouse CD1d tetramers were produced as previ-
ously described [66]. Biotinylated antibodies were detected using
Alexa Fluor 488–conjugated streptavidin (Invitrogen Life Tech-
nologies, Eugene, OR). Anti–IL-10R (1B1.3a; rat IgG1) was
purchased from BD Biosciences. Purified control rat IgG was
purchased from Sigma-Aldrich (Castle Hill, Australia).
Flow cytometry
The labelling of hepatic MNC for cell surface antigens and
intracellular cytokines for FACS analysis was performed as
previously described [40,65]. Flow cytometric analysis was
performed on a FACScalibur flow cytometer and analysed using
Cell Quest Pro (BD Biosciences) and FlowJo Software (Tree Star,
Ashland, OR). Cell populations in the liver were defined as
follows: CD4
+ T cells (CD4
+ TCRb
+), CD8
+ T cells (CD8a
+
TCRb
+), B cells (B220
+ CD19
+), neutrophils (CD11b
+ Ly6G
+),
macrophages/monocytes (CD11b
+ Ly6C
+), dendritic cells (DC;
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hi MHCII
hi), NK cells (NK1.1
+ TCRb
2), NKT cells
(CD1d a-GalCer tetramer
+ TCRb
+ or NK1.1
+ TCRb
+,a s
indicated in the text).
In vivo a-GalCer treatment
a-GalCer (KRN7000) was provided by the Kirin Pharmaceu-
tical Research laboratories (Kirin Brewery, Gumna, Japan) and
was prepared in saline/0.5% (w/v) polysorbate-20. No endotoxin
contamination was detected in the supplied material (Tomoaki
Kuwaki, Kirin Brewery, personal communication). Mice received
a single i.p. injection of 2 mg a-GalCer or vehicle control (saline/
0.5% (w/v) polysorbate-20) at the times indicated in the text.
Delivery of a-GalCer in bone marrow–derived dendritic
cells (BMDC)
Bone marrow cells were isolated from the femurs of C57BL/6
mice and cultured in 20 ng/ml recombinant mouse GM-CSF and
20 ng/ml recombinant mouse IL-4 (R&D Systems, Minneapolis,
MN), as previously described [37]. BMDC were supplemented
with fresh media and 100 ng/ml a-GalCer or vehicle control on
days 6–8 of culture. BMDC (5610
5) were injected i.v. at the times
indicated in the text.
IL-10 and IL-4 neutralisation
Mice were injected i.p. with 1 mg of anti-IL-10R mAb (1B1.3a)
or purified control rat IgG (Sigma-Aldrich) at day 12 p.i.. Mice
were injected i.p. with 1 mg of anti–IL-4 mAb (11B11) or purified
control rat IgG on days 14, 16 and 18 p.i..
Serum cytokine analysis
Serum samples were analysed for IFNc and TNF using a
cytometric bead array (mouse inflammation kit, BD Biosciences)
on a FACScan cytometer equipped with Cell Quest Pro and CBA
Software (BD Biosciences).
ELISPOT analysis
The frequency of liver MNC producing IFNc or TNF was
determined by direct ex vivo ELISPOT assay, as previously
described [67] using mAbs R46A2 and TN3-19.12, respectively,
as capture antibodies and polyclonal anti-murine IFNc or TNF as
detecting antibodies (BD Biosciences).
Real-time reverse transcriptase–polymerase chain reaction
Total RNA was extracted from liver tissue using TRIzol reagent
(Invitrogen Life Technologies), and an RNeasy Mini Kit with on-
column DNase digestion (Qiagen, Valencia, CA). RNA samples
were reverse transcribed into cDNA using the High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA) according to the manufacturer’s instructions. The
number of IL-10, TGFb, IL-4, IL-13 and HPRT (house-keeping
gene) cDNA molecules in each sample were calculated using
Taqman Gene Expression Assays (Applied Biosystems). All real-
time RT-PCR were performed on a Corbett Research RG-3000
Rotor Gene (Corbett Life Sciences, Sydney, Australia). Standard
curves were generated with known amounts of cDNA for each
gene, and the number of cytokine molecules per 1,000 HPRT
molecules in each sample was calculated.
Statistical analysis
Statistical significance of differences in parasite burdens over a
time course of infection were determined using a one way analysis of
variance (ANOVA) followed by a Tukey’s Post-Test. Statistical
significance of other parameters were determined using a Mann-
Whitney U test or Student’s t-test. All analysis was conducted using
GraphPad Prism version 4.03 for Windows (GraphPad Software,
San Diego, CA) and p,0.05 was considered statistically significant.
Supporting Information
Figure S1 The Number of IFNc- or TNF-Producing Cells Is
Similar in L. donovani-Infected C57BL/6 Mice and Mice Lacking
NKT Cells. Female C57BL/6 (closed squares), B6.Ja18
2/2 (open
circles) and B6.CD1d
2/2 (open triangles) mice were infected with
L. donovani, and the total numbers of IFNc- (A) or TNF-producing
cells (B) in the liver were measured by ELISPOT from day 7 to
day 56 p.i.. Data represent the mean 6 SEM of cytokine-
producing cells from four mice per group for each time point.
Found at: doi:10.1371/journal.ppat.1000028.s001 (1.24 MB TIF)
Figure S2 a-GalCer-Treated Mice Recover at Later Time
Points. C57BL/6 mice were infected with L. donovani and treated
with either vehicle control (open bars) or 2 mg a-GalCer (closed
bars) i.p. on day 14 p.i.. Parasite burdens were determined in the
liver at day 14 p.i. in untreated mice (grey bars; baseline parasite
burden), 1 wk later in treated groups or 56 d later in treated
groups, as indicated. Statistical differences of p,0.001 (***) for
vehicle versus a-GalCer treatment are indicated (n=4 mice per
group).
Found at: doi:10.1371/journal.ppat.1000028.s002 (0.90 MB TIF)
Figure S3 IFNc Is Readily Detected in Hepatic NK Cells and
Conventional T Cells 14 Days After L. donovani Infection. Naı ¨ve
C57BL/6 mice or mice infected with L. donovani were treated with
vehicle control on day 14 p.i. and killed 2 h later for FACS
analysis of intracellular IFNc production, as indicated. Hepatic
lymphocytes were labelled with CD1d/a-GalCer tetramers, anti-
abTCR, anti-NK1.1, and anti-IFNc. T cells (A) and NK cells (B)
were electronically gated as shown, and examined for expression
of IFNc or isotype control antibody. The percentage of gated cells
is shown in the top left-hand corner. One representative animal of
four examined is shown.
Found at: doi:10.1371/journal.ppat.1000028.s003 (5.38 MB TIF)
Figure S4 Liver Cell Composition Following a-GalCer Treat-
ment. C57BL/6 mice were infected with L. donovani and treated
with either vehicle control (open bars) or 2 mg a-GalCer (closed
bars) i.p. on day 14 p.i.. Liver cell numbers were determined by
FACS in naı ¨ve mice (hatched bars), at day 14 p.i. in untreated
mice (grey bars), and 1 wk later in treated groups, as indicated
(n=4 mice per group).
Found at: doi:10.1371/journal.ppat.1000028.s004 (4.14 MB TIF)
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